|
New Bexsero Schedule: MMWR December 12, 2024 / 73(49);1124–1128
On October 24, 2024, the Advisory Committee on Immunization Practices (ACIP) updated its recommendations for MenB-4C to align the dosing interval and schedule with the new Food and Drug Administration (FDA) label and harmonize with recommendations for MenB-FHbp (Trumenba, Pfizer, Inc.) vaccine. ACIP now recommends MenB-4C as a 2-dose series with doses administered at intervals of 0 and 6 months for healthy adolescents and young adults aged 16–23 years based on shared clinical decision-making and as a 3-dose series with doses administered at 0, 1–2, and 6 months for persons aged ≥10 years at increased risk.
|
|
VBI Vaccine Recall for PreHevbrio
VBI Vaccines, the manufacturer of the PreHevbrio brand of HepB vaccine, declared bankruptcy and is ending business operations. PreHevbrio is no longer being distributed. Customers with the product are asked to destroy or return remaining doses. The recall is not related to vaccine safety or quality. All properly administered doses of PreHevbrio are valid HepB vaccinations and do not need to be repeated.
|
|
|
|
Considerations for COVID-19 & Nirsevimab
VFC providers will be allowed a flexible, time-limited ramp-up period to meet the private inventory requirement for COVID-19 vaccine and nirsevimab. During this time,
awardees will not require VFC providers to meet the private inventory minimum requirements for COVID-19 vaccine or nirsevimab if they do not intend to vaccinate their private pay patients. VFC providers are required to meet the private inventory requirement no later than August 31, 2025. For those VFC providers who maintain private stock of COVID-19 vaccine or nirsevimab and vaccinating privately insured children, bidirectional borrowing of COVID-19 vaccine and nirsevimab will be allowed for the 2024-2025 respiratory virus season at the discretion of the awardee and as described below. VFC providers should ensure they have funds to procure sufficient private stock before COVID-19 vaccine or nirsevimab is borrowed from VFC stock for a non-VFC eligible child.
|
|
|
2025 Immunization Schedules
On November 21, CDC posted the 2025 recommended immunization schedule for adults, and the schedule for children & adolescents, with a version for healthcare providers and another for parents. CDC will publish the schedule along with additional commentary about its changes in MMWR in January. In the meantime, on the CDC website you may view a section-by-section description of what changed on the child and adolescent schedule for 2025.
|
|
⭐ Gold Star Awards (Oct 1 - Nov 30, 2024)
Outstanding VVFC Compliance
Augusta Pediatrics, Fishersville
Lewis Gale Phys – Valleyview, Roanoke
Jonesville Family Health, Jonesville
Process Improvement
Piedmont Health District, Central Region
Clinch River Health Services, Dungannon
|
|
Adult Vaccine Update
Additional COVID-19 Doses for Adults: MMWR December 12, 2024 / 73(49);1118–1123
In October 2024, ACIP recommended that all persons aged ≥65 years and persons aged 6 months–64 years with moderate or severe immunocompromise receive a second 2024–2025 COVID-19 vaccine dose 6 months after their last dose. Further, ACIP recommended that persons aged ≥6 months with moderate or severe immunocompromise may receive additional doses based on shared clinical decision-making.
Adults aged ≥65 years should receive 2 doses of 2024–2025 COVID-19 vaccine, and persons aged ≥6 months with moderate or severe immunocompromise should receive ≥2 doses to protect against severe COVID-19.
Heplisav-B Vaccine During Pregnancy: MMWR December 5, 2024 / 73(48);1106
On September 11, 2024, the Food and Drug Administration approved updates to the package insert for Heplisav-B ... to include human data that do not suggest an increased risk for both major birth defects and miscarriage.
Providers can now administer Engerix-B, Heplisav-B, Recombivax HB, or Twinrix to pregnant persons needing HepB vaccination.
|
|
|
|
